

09 November 2020

Dr Andrew Carroll
Plant & Food Research
Batchelar Road
Plant & Food Research, Batchelar Road
Palmerston North 4474

Dear Dr Carroll,

Re:	Ethics ref:	20/NTB/260
	Study title:	A pilot human study to investigate the effect of gold kiwifruit consumption on transcriptomic changes in buccal epithelial swabs: A novel platform to establish the bio-efficacy and appropriate health applications of kiwifruit.

I am pleased to advise that this application has been approved by the Northern B Health and Disability Ethics Committee. This decision was made through the HDEC-Expedited Review pathway.

Conditions of HDEC approval

HDEC approval for this study is subject to the following conditions being met prior to the commencement of the study in New Zealand. It is your responsibility, and that of the study's sponsor, to ensure that these conditions are met. No further review by the Northern B Health and Disability Ethics Committee is required.

Standard conditions:

1. Before the study commences at *any* locality in New Zealand, all relevant regulatory approvals must be obtained.
2. Before the study commences at *any* locality in New Zealand, it must be registered in a clinical trials registry. This should be a WHO-approved registry (such as the Australia New Zealand Clinical Trials Registry, www.anzctr.org.au) or <https://clinicaltrials.gov/>.
3. Before the study commences at *each given* locality in New Zealand, it must be authorised by that locality in Online Forms. Locality authorisation confirms that the locality is suitable for the safe and effective conduct of the study, and that local research governance issues have been addressed.

After HDEC review

Please refer to the *Standard Operating Procedures for Health and Disability Ethics Committees* (available on www.ethics.health.govt.nz) for HDEC requirements relating to amendments and other post-approval processes.


Your next progress report is due by 09 November 2021.

Participant access to ACC

This clinical trial is to be conducted principally for the benefit of the manufacturer or distributor of the medicine or item being trialled. Section 32 of the Accident Compensation Act 2001 provides that participants injured as a result of treatment received as part of this trial will **not** be eligible for publicly-funded compensation through the Accident Compensation Corporation (ACC).

Please don't hesitate to contact the HDEC secretariat for further information. We wish you all the best for your study.

Yours sincerely,



Mrs Kate O'Connor
Chairperson
Northern B Health and Disability Ethics Committee

Encl: appendix A: documents submitted
appendix B: statement of compliance and list of members

Appendix A
Documents submitted

<i>Document</i>	<i>Version</i>	<i>Date</i>
Covering Letter	1	02 October 2020
CV for CI	1	02 October 2020
Evidence of sponsor insurance	1	02 October 2020
Protocol	1	02 October 2020
Survey/questionnaire: PoMS Questionnaire	1	02 October 2020
Survey/questionnaire: Health questionnaire	1	02 October 2020
PIS/CF: Participant information and consent form	1	02 October 2020
Evidence of scientific review	1	02 October 2020
Application		05 October 2020
Covering Letter: Reply to reviewed application	2	27 October 2020
Protocol: revised and tracked	2	27 October 2020
Protocol: revised and clean	2	27 October 2020
PIS/CF: revised and tracked	2	27 October 2020
PIS/CF: revised and clean	2	27 October 2020
Response to Request for Further Information		

Appendix B Statement of compliance and list of members

Statement of compliance

The Northern B Health and Disability Ethics Committee:

- is constituted in accordance with its Terms of Reference
- operates in accordance with the *Standard Operating Procedures for Health and Disability Ethics Committees*, and with the principles of international good clinical practice (GCP)
- is approved by the Health Research Council of New Zealand's Ethics Committee for the purposes of section 25(1)(c) of the Health Research Council Act 1990
- is registered (number 00008715) with the US Department of Health and Human Services' Office for Human Research Protection (OHRP).

List of members

<i>Name</i>	<i>Category</i>	<i>Appointed</i>	<i>Term Expires</i>
Mr John Hancock	Lay (the law)	14/12/2015	14/12/2018
Dr Nora Lynch	Non-lay (health/disability service provision)	19/03/2019	19/03/2026
Miss Tangihaere Macfarlane	Lay (consumer/community perspectives)	20/05/2017	20/05/2020
Mrs Kate O'Connor	Lay (ethical/moral reasoning)	14/12/2015	14/12/2018
Mrs Stephanie Pollard	Non-lay (intervention studies)	01/07/2015	01/07/2018
Mrs Leesa Russell	Non-lay (intervention studies), Non-lay (observational studies)	14/12/2015	14/12/2018
Ms Susan Sherrard	Lay (consumer/community perspectives)	19/03/2019	19/03/2022
Mrs Jane Wylie	Non-lay (intervention studies)	20/05/2017	20/05/2020

Unless members resign, vacate or are removed from their office, every member of HDEC shall continue in office until their successor comes into office (HDEC Terms of Reference)

<http://www.ethics.health.govt.nz>